The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 306.00
Bid: 308.00
Ask: 308.50
Change: 14.50 (4.97%)
Spread: 0.50 (0.162%)
Open: 298.00
High: 308.00
Low: 285.50
Prev. Close: 291.50
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Trading Update

14 Oct 2020 07:00

RNS Number : 9815B
Synthomer PLC
14 October 2020
 

October 14th 2020

 

Synthomer plc

 

Q3 Trading Update

 

FY2020 EBITDA guidance raised 10%, interim dividend reinstated and pro forma leverage expected to reduce to circa 2.0x EBITDA by end of 2020

 

Synthomer plc ("Synthomer" or "the Group") today brings forward its update on trading for the third quarter ("Q3") ended September 30th 2020.

 

Strong trading momentum across all three business divisions

 

Performance Elastomers volumes and margins are ahead of prior year reflecting strong demand in Nitrile Latex following the COVID-19 pandemic and improved conditions in SBR latex through Q3.

 

Functional Solutions continued to benefit from the integration of OMNOVA and likewise is trading ahead of prior year albeit some market sectors are demonstrating stronger resilience than others. End market and geographic diversification remains a key strength of our Functional Solutions business.

 

Industrial Specialities continued to improve in Q3 following a weaker Q2 impacted by COVID-19. Current run rate volumes and margins are on or above prior year.

 

FY EBITDA guidance raised 10%

 

At the time of its Interim Results in August, the Group said that it expected FY 2020 EBITDA to be broadly-in-line with market consensus of £211 million (source Teneo). Synthomer now expects FY 2020 EBITDA to be circa £232 million, 10% higher than where it was envisaged to be in August.

 

Proforma leverage expected to reduce to circa 2.0x EBITDA

 

The Group remains highly cash generative and now expects proforma leverage to reduce to circa 2.0x net debt to EBITDA by December 2020.

 

Interim dividend reinstated

 

As a result of the Group's strong trading performance and cash generation, the Board has decided to reinstate the interim dividend which was suspended in April. The Board has declared an interim dividend of 3.0 pence per share payable on November 10th 2020 to shareholders on the register at close of business on October 23rd 2020. The Board has also fully reinstated its existing dividend policy and intends to pay a final dividend in line with its capital policy.

 

Further strategic progress

 

The integration of OMNOVA is proceeding ahead of schedule. As previously stated, the Group now expects synergies to achieve a $20 million run rate by the end of year (increased from $15 million) and a $40 million run rate by the end of 2022 (increased from $30 million).

 

In August, the Group confirmed that it was in a consultation process with employees at its SBR site in Oulu (Finland) concerning future options for the site. The consultation process at Oulu is complete and the decision has been made to close this site by the end of Q1 2021. Consultations are continuing at Marl (Germany) with an outcome expected in Q4 this year. Synthomer remains committed to the SBR markets in Europe and is confident of being able to service customers from its Central European asset base. 

 

Our additional Nitrile Latex capacity in Malaysia is on schedule for beneficial operation in Q4 2021 to further support the strong demand we have seen following the COVID-19 pandemic.

 

 

Calum MacLean, Chief Executive of Synthomer said:

 

"This is a very encouraging performance with all business divisions performing ahead of prior year. Alongside this strong momentum, we have made significant strategic progress, with a decision to close our site in Oulu and the integration of OMNOVA continuing ahead of our initial expectations. This underpins our confidence for the remainder of this year and beyond leading to an upgrade to our guidance for the full year and reinstating our interim dividend."

 

 

Further information:

 

The Company will hold a conference call for investors and analysts at 0900 BST today:

Dial in number: 08003589473 PIN: 69896742#

 

 

Calum MacLean, Chief Executive Officer

 

Steve Bennett, Chief Financial Officer

Tel: + 44 1279 436211

Tim Hughes, President, Corporate Development

 

 

 

Charles Armitstead/ Matt Denham, Teneo

Tel: + 44 7703 330 269/ + 44 7825 735596

 

 

Investor Seminar

Synthomer will be hosting an Investor Seminar on Wednesday 18th November to focus on the Group's strategy post its acquisition of OMNOVA, with a particular focus on its Functional Solutions business.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUOVBRRUURAAA
Date   Source Headline
18th Dec 20147:00 amRNSBoard Changes
18th Nov 20147:00 amRNSAppointment of Group Chief Executive
28th Oct 20147:00 amRNSInterim Management Statement
22nd Oct 20143:00 pmRNSAcquisition
17th Oct 20141:03 pmRNSDirector/PDMR Shareholding
16th Oct 20143:56 pmRNSDirector/PDMR Shareholding
15th Oct 201412:35 pmRNSDirector/PDMR Shareholding
14th Oct 20142:40 pmRNSDirector/PDMR Shareholding
13th Oct 20149:35 amRNSDirector Declaration
11th Aug 20147:00 amRNSInterim Results
11th Jul 20147:00 amRNSTrading update
1st Jul 20147:00 amRNSAdrian Whitfield to step down as CEO
23rd Jun 201412:01 pmRNSHolding(s) in Company
30th May 20149:24 amRNSHolding(s) in Company
15th May 20144:26 pmRNSDirector/PDMR Shareholding
8th May 201411:25 amRNSDirector/PDMR Shareholding
7th May 20144:35 pmRNSDirector/PDMR Shareholding
1st May 20142:47 pmRNSResult of AGM
1st May 20147:00 amRNSInterim Management Statement
14th Apr 20149:23 amRNSHolding(s) in Company
9th Apr 20143:08 pmRNSHolding(s) in Company
9th Apr 201411:26 amRNSHolding(s) in Company
31st Mar 20149:40 amRNSAnnual Financial Report
14th Mar 20144:17 pmRNSHolding(s) in Company
14th Mar 201411:48 amRNSHolding(s) in Company
12th Mar 20142:40 pmRNSDirector/PDMR Shareholding
6th Mar 20144:15 pmRNSDirector/PDMR Shareholding
6th Mar 20144:12 pmRNSDirector/PDMR Shareholding
5th Mar 20147:00 amRNSChanges to Board Committees
4th Mar 20142:14 pmRNSHolding(s) in Company
28th Feb 20147:01 amRNSPreliminary Results
13th Feb 20142:57 pmRNSHolding(s) in Company
16th Jan 20148:53 amRNSHolding(s) in Company
16th Jan 20147:00 amRNSDirectorate Change
6th Dec 20139:34 amRNSHolding(s) in Company
22nd Nov 20134:08 pmRNSHolding(s) in Company
20th Nov 201311:45 amRNSHolding(s) in Company
19th Nov 20137:00 amRNSCapital Markets Day
12th Nov 20135:06 pmRNSHolding(s) in Company
8th Nov 20133:03 pmRNSHolding(s) in Company
7th Nov 20137:00 amRNSInterim Management Statement
29th Oct 20131:45 pmRNSHolding(s) in Company
14th Oct 20133:55 pmRNSHolding(s) in Company
22nd Aug 201311:18 amRNSHolding(s) in Company
16th Aug 201312:36 pmRNSDirector/PDMR Shareholding
13th Aug 20137:00 amRNSInterim Results
12th Aug 20131:37 pmRNSHolding(s) in Company
7th Aug 20133:18 pmRNSHolding(s) in Company
4th Jul 20133:37 pmRNSHolding(s) in Company
28th Jun 20134:21 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.